Advanced

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells InVitro or prostate cancer xenografts in vivo

Denmeade, SR; Litvinov, I; Sokoll, LJ; Lilja, Hans LU and Isaacs, JT (2003) In The Prostate 56(1). p.45-53
Abstract
BACKGROUND. Prostate-specific antigen (PSA) is produced in high amounts by normal and malignant prostate cancer cells. PSA is a serine protease with substrates that include semenogelin I and II, insulin-like growth factor binding protein 3, fibronectin, and laminin. PSA, via its enzymatic activity, may play a role in growth, invasion, and metastasis of prostate cancer cells. Recent data also suggest that the PSA protein itself, independent of enzymatic activity, may also function as an endothelial cell-specific inhibitor of angiogenesis. METHODS. Human (PC3, DU145) and rat (AT2, AT6) prostate cancer cell lines were transfected with the full PSA gene encoding preproPSA protein. PSA-producing clones of each cell line were selected and the... (More)
BACKGROUND. Prostate-specific antigen (PSA) is produced in high amounts by normal and malignant prostate cancer cells. PSA is a serine protease with substrates that include semenogelin I and II, insulin-like growth factor binding protein 3, fibronectin, and laminin. PSA, via its enzymatic activity, may play a role in growth, invasion, and metastasis of prostate cancer cells. Recent data also suggest that the PSA protein itself, independent of enzymatic activity, may also function as an endothelial cell-specific inhibitor of angiogenesis. METHODS. Human (PC3, DU145) and rat (AT2, AT6) prostate cancer cell lines were transfected with the full PSA gene encoding preproPSA protein. PSA-producing clones of each cell line were selected and the amount of enzymatically active PSA produced by each cell line determined using a PSA-specific fluorescent peptide substrate. In vitro and in vivo growth characteristics of PSA-producing transfectants were compared to neomycin controls and wild type cells. RESULTS. All selected clones produced and secreted PSA (5-120 ng/ml/10(5) cells). None of the PSA-transfected cell lines produced detectable amounts of enzymatically active PSA. Production of enzymatically inactive PSA by prostate cancer cell lines did not alter growth kinetics in vitro. PSA-producing xenograft doubling times in vivo were similar to neomycin controls and wild type. CONCLUSION. Although recent reports suggest the PSA protein itself maybe antiangiogenic, our results demonstrate that production of PSA protein by prostate cancer cells does not significantly alter growth in vitro or in vivo. Prostate 56: 45-53, 2003. (C) 2003 Wiley-Liss, Inc. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
enzymatic activity, prostate-specific antigen, growth
in
The Prostate
volume
56
issue
1
pages
45 - 53
publisher
John Wiley & Sons
external identifiers
  • wos:000183052900006
  • pmid:12746846
  • scopus:0037566830
ISSN
0270-4137
DOI
language
English
LU publication?
yes
id
0000b85b-5eac-44f1-bd40-748a37b0f6e5 (old id 309977)
date added to LUP
2007-08-29 11:38:57
date last changed
2018-05-29 11:08:52
@article{0000b85b-5eac-44f1-bd40-748a37b0f6e5,
  abstract     = {BACKGROUND. Prostate-specific antigen (PSA) is produced in high amounts by normal and malignant prostate cancer cells. PSA is a serine protease with substrates that include semenogelin I and II, insulin-like growth factor binding protein 3, fibronectin, and laminin. PSA, via its enzymatic activity, may play a role in growth, invasion, and metastasis of prostate cancer cells. Recent data also suggest that the PSA protein itself, independent of enzymatic activity, may also function as an endothelial cell-specific inhibitor of angiogenesis. METHODS. Human (PC3, DU145) and rat (AT2, AT6) prostate cancer cell lines were transfected with the full PSA gene encoding preproPSA protein. PSA-producing clones of each cell line were selected and the amount of enzymatically active PSA produced by each cell line determined using a PSA-specific fluorescent peptide substrate. In vitro and in vivo growth characteristics of PSA-producing transfectants were compared to neomycin controls and wild type cells. RESULTS. All selected clones produced and secreted PSA (5-120 ng/ml/10(5) cells). None of the PSA-transfected cell lines produced detectable amounts of enzymatically active PSA. Production of enzymatically inactive PSA by prostate cancer cell lines did not alter growth kinetics in vitro. PSA-producing xenograft doubling times in vivo were similar to neomycin controls and wild type. CONCLUSION. Although recent reports suggest the PSA protein itself maybe antiangiogenic, our results demonstrate that production of PSA protein by prostate cancer cells does not significantly alter growth in vitro or in vivo. Prostate 56: 45-53, 2003. (C) 2003 Wiley-Liss, Inc.},
  author       = {Denmeade, SR and Litvinov, I and Sokoll, LJ and Lilja, Hans and Isaacs, JT},
  issn         = {0270-4137},
  keyword      = {enzymatic activity,prostate-specific antigen,growth},
  language     = {eng},
  number       = {1},
  pages        = {45--53},
  publisher    = {John Wiley & Sons},
  series       = {The Prostate},
  title        = {Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells InVitro or prostate cancer xenografts in vivo},
  url          = {http://dx.doi.org/},
  volume       = {56},
  year         = {2003},
}